Articles

For patients with severe hypertension that remains uncontrolled despite medical therapy, radiofrequency (RF) energy can be used in the renal vessels to block nerves involved with the sympathetic...

A new class of antiplatelet therapy drug pending U.S. Food and Drug Administration (FDA) clearance may offer greater benefits over clopidogrel (Plavix) the current standard of therapy. The new...

March 18, 2010 – The U.S. Food and Drug Administration (FDA) today added a boxed warning to the anti-blood clotting drug Plavix (clopidogrel), alerting patients and healthcare professionals that...

March 17, 2010 – New Results from PLATO trial suggest ticagrelor (Brilinta) leads to lower mortality and no increased risk of bleeding when compared to clopidogrel (Plavix) in patients with acute...

March 16, 2010 — Lowering blood pressure to normal levels — below currently recommended levels — did not significantly reduce the combined risk of fatal or nonfatal cardiovascular disease events...

March 3, 2010 – Pharmaceutical companies will struggle to profit from the cardiovascular disease (CVD) market over the next decade despite growing drug usage, according to new market research from...

In August Daiichi Sankyo and Eli Lilly and Company launched U.S. sales of Effient (prasugrel), a new antiplatelet medication to prevent stent thrombosis, which clinical studies show to be more...

Gregg W. Stone, M.D., offered a preview Sept. 10 of some of the key, late-breaking clinical trials and trends in interventional cardiology that will be presented during the Transcatheter...

September 1, 2009 – AstraZeneca last week announced results from the phase III head to head trial, PLATO (A Study of Platelet Inhibition and Patient Outcomes), which demonstrate that ticagrelor (...

June 1, 2009 - Results and updates from eight studies were presented during a late-breaking trials session at Heart Failure 2009, May 30 – June 2 in Nice, France.

Professor John McMurray,...